- Home
- PPBT vs PSTV Comparison
PPBT vs PSTV Comparison
Compare PPBT & PSTV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PPBT
- PSTV
- Stock Information
- Founded
- PPBT 2010
- PSTV 1996
- Country
- PPBT Israel
- PSTV United States
- Employees
- PPBT N/A
- PSTV N/A
- Industry
- PPBT Biotechnology: Pharmaceutical Preparations
- PSTV Medical/Dental Instruments
- Sector
- PPBT Health Care
- PSTV Health Care
- Exchange
- PPBT Nasdaq
- PSTV Nasdaq
- Market Cap
- PPBT 9.2M
- PSTV 7.9M
- IPO Year
- PPBT N/A
- PSTV N/A
- Fundamental
- Price
- PPBT $2.51
- PSTV $1.17
- Analyst Decision
- PPBT Strong Buy
- PSTV Strong Buy
- Analyst Count
- PPBT 2
- PSTV 2
- Target Price
- PPBT $126.50
- PSTV $14.00
- AVG Volume (30 Days)
- PPBT 61.9K
- PSTV 109.0K
- Earning Date
- PPBT 11-15-2024
- PSTV 11-14-2024
- Dividend Yield
- PPBT N/A
- PSTV N/A
- EPS Growth
- PPBT N/A
- PSTV N/A
- EPS
- PPBT N/A
- PSTV N/A
- Revenue
- PPBT N/A
- PSTV $5,509,000.00
- Revenue This Year
- PPBT N/A
- PSTV $11.13
- Revenue Next Year
- PPBT N/A
- PSTV N/A
- P/E Ratio
- PPBT N/A
- PSTV N/A
- Revenue Growth
- PPBT N/A
- PSTV 113.20
- 52 Week Low
- PPBT $2.43
- PSTV $1.15
- 52 Week High
- PPBT $23.20
- PSTV $2.78
- Technical
- Relative Strength Index (RSI)
- PPBT 28.04
- PSTV 37.57
- Support Level
- PPBT $2.50
- PSTV $1.17
- Resistance Level
- PPBT $2.82
- PSTV $1.42
- Average True Range (ATR)
- PPBT 0.38
- PSTV 0.11
- MACD
- PPBT 0.04
- PSTV -0.01
- Stochastic Oscillator
- PPBT 5.10
- PSTV 3.03
About PPBT Purple Biotech Ltd.
Purple Biotech Ltd is a clinical-stage company focused on advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, and to create treatments for people with cancer. Its oncology pipeline includes NT219 and CM24.
About PSTV PLUS THERAPEUTICS Inc.
Plus Therapeutics Inc is a clinical-stage pharmaceutical company that focuses on discovering, developing, and delivering complex treatments for patients with cancer and rare diseases. The company is working on a range of potential products, with its main programs targeting recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). One of its key candidates, rhenium (186Re) obisbemeda, is specifically designed to treat central nervous system (CNS) cancers such as GBM, LM, and pediatric brain cancers (PBC).